Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2019 Dec;23(67):1–40. doi: 10.3310/hta23670

Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.

Clara Carreras-Abad, Madeleine Cochet, Tom Hall, Laxmee Ramkhelawon, Asma Khalil, Elisabeth Peregrine, Latha Vinayakarao, Sharmila Sivarajan, Rosol Hamid, Tim Planche, Elizabeth Sheridan, Stephen Winchester, Jane Plumb, Abdelmajid Djennad, Nick Andrews, Kirsty Le Doare, Paul Heath
PMCID: PMC6936166  PMID: 31855555

Abstract

BACKGROUND

Group B streptococcus is the leading cause of infection in infants. Currently, intrapartum antibiotic prophylaxis is the major strategy to prevent invasive group B streptococcus disease. However, intrapartum antibiotic prophylaxis does not prevent maternal sepsis, premature births, stillbirths or late-onset disease. Maternal vaccination may offer an alternative strategy. Multivalent polysaccharide protein conjugate vaccine development is under way and a serocorrelate of protection is needed to expedite vaccine licensure.

OBJECTIVES

The ultimate aim of this work is to determine the correlate of protection against the major group B streptococcus disease-causing serotypes in infants in the UK. The aim of this feasibility study is to test key operational aspects of the study design.

DESIGN

Prospective cohort study of pregnant women and their infants in a 6-month period (1 July to 31 December 2018).

SETTING

Five secondary and tertiary hospitals from London and South England. National iGBS disease surveillance was conducted in all trusts in England and Wales.

PARTICIPANTS

Pregnant women aged ≥ 18 years who were delivering at one of the selected hospitals and who provided consent during the study period. There were no exclusion criteria.

INTERVENTIONS

No interventions were performed.

MAIN OUTCOME MEASURES

(1) To test the feasibility of collecting serum at delivery from a large cohort of pregnant women. (2) To test the key operational aspects for a proposed large serocorrelates study. (3) To test the feasibility of collecting samples from those with invasive group B streptococcus.

RESULTS

A total of 1823 women were recruited during the study period. Overall, 85% of serum samples were collected at three sites collecting only cord blood. At the two sites collecting maternal, cord and infant blood samples, the collection rate was 60%. A total of 614 women were screened for group B streptococcus with a colonisation rate of 22% (serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib, 14% V and 1% IV). A blood sample was collected from 34 infants who were born to colonised women. Maternal and infant blood and the bacterial isolates for 15 newborns who developed invasive group B streptococcal disease during the study period were collected (serotype distribution: 29% III, 29% II, 21% Ia, 7% Ib, 7% IV and 7% V).

LIMITATIONS

Recruitment and sample collection were dependent on the presence of research midwives rather than the whole clinical team. In addition, individualised consent limited the number of women who could be approached each day, and site set-up for the national surveillance study and the limited time period of this feasibility study limited recruitment of all eligible participants.

CONCLUSIONS

We have verified the feasibility of collecting and processing rectovaginal swabs and blood samples in pregnant women, as well as samples from those with invasive group B streptococcal disease. We have made recommendations for the recruitment of cases within the proposed GBS3 study and for controls both within GBS3 and as an extension of this feasibility study.

FUTURE WORK

A large case-control study comparing specific immunoglobulin G levels in mothers whose infants develop invasive group B streptococcal disease with those in colonised mothers whose infants do not develop invasive group B streptococcal disease is recommended.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN49326091; IRAS project identification number 246149/REC reference number 18/WM/0147.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 67. See the NIHR Journals Library website for further project information.

Plain language summary

Group B streptococcus is often carried by healthy women and usually causes no problems. Group B streptococcus may be passed from mother to child, primarily through the birth canal, and, in rare cases, can cause serious disease (i.e. pneumonia, sepsis or meningitis) and even death in babies. It may be possible to prevent group B streptococcus disease in babies by giving a vaccine to pregnant women. The reason for vaccinating the mother is so that she can pass on protection (antibodies) during the pregnancy to her baby. A vaccine is currently being developed against group B streptococcus that aims to boost this protection. To help vaccine development progress faster, we need to find out how much antibody is actually needed to protect babies from group B streptococcus disease. A large study is needed to address this question; therefore, we have performed a feasibility study to assess the practicalities of performing this large study. Specifically, we will assess (1) women’s willingness to participate in a swabbing and cord blood study, (2) the ability to collect swabs and cord blood once recruited, (3) the ability to identify group B streptococcus disease in this population and (4) the laboratory processing of samples. We recruited 1823 pregnant women from five maternity units in England in a 6-month period: 22% of all women delivering at all sites and 74% of those women who were approached. In three hospitals, cord blood samples from 85% of 1201 women were collected. In two hospitals, we collected 60% of maternal blood samples, 53% of cord blood samples and 99% of swabs from the vagina and rectum from 622 women. A total of 22% of these women carried group B streptococcus in their vagina or gut and we collected blood samples from 34 healthy babies born to these women. During the study, we collected samples from 15 babies who had developed severe group B streptococcus disease; four babies were born to women participating in the study and the rest were identified through national surveillance. In conclusion, we have verified the feasibility of collecting and processing swabs from the vagina and rectum and blood samples in pregnant women, as well as samples from babies who developed group B streptococcus disease. In addition, we have identified a number of strategies that could be adopted in a future study in order to increase recruitment and sample collection.

Full text of this article can be found in Bookshelf.

References

  1. Heath PT, Culley FJ, Jones CE, Kampmann B, Le Doare K, Nunes MC, et al. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis 2017;17:e223–e234. https://doi.org/10.1016/S1473-3099(17)30232-3 doi: 10.1016/S1473-3099(17)30232-3. [DOI] [PubMed]
  2. Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, et al. Infant Group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S160–S172. https://doi.org/10.1093/cid/cix656 doi: 10.1093/cid/cix656. [DOI] [PMC free article] [PubMed]
  3. Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S100–S111. https://doi.org/10.1093/cid/cix658 doi: 10.1093/cid/cix658. [DOI] [PMC free article] [PubMed]
  4. Russell NJ, Seale AC, O’Sullivan C, Le Doare K, Heath PT, Lawn JE, et al. Risk of early-onset neonatal Group B streptococcal disease with maternal colonization worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S152–S159. https://doi.org/10.1093/cid/cix655 doi: 10.1093/cid/cix655. [DOI] [PMC free article] [PubMed]
  5. Heath PT, Balfour GF, Tighe H, Verlander NQ, Lamagni TL, Efstratiou A, HPA GBS Working Group. Group B streptococcal disease in infants: a case control study. Arch Dis Child 2009;94:674–80. https://doi.org/10.1136/adc.2008.148874 doi: 10.1136/adc.2008.148874. [DOI] [PubMed]
  6. Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, et al. Estimates of the burden of Group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis 2017;65:S200–S219. https://doi.org/10.1093/cid/cix664 doi: 10.1093/cid/cix664. [DOI] [PMC free article] [PubMed]
  7. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15–20. https://doi.org/10.1056/NEJM200001063420103 doi: 10.1056/NEJM200001063420103. [DOI] [PubMed]
  8. Le Doare K, O’Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review. Clin Infect Dis 2017;65:S143–S151. https://doi.org/10.1093/cid/cix654 doi: 10.1093/cid/cix654. [DOI] [PMC free article] [PubMed]
  9. Bekker V, Bijlsma MW, van de Beek D, Kuijpers TW, van der Ende A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis 2014;14:1083–9. https://doi.org/10.1016/S1473-3099(14)70919-3 doi: 10.1016/S1473-3099(14)70919-3. [DOI] [PubMed]
  10. C O’Sullivan, T Lamagni, A Efstratiou, et al. Group B Streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014–15. Arch Dis Childhood 2016;101(Suppl. 1):A2. https://doi.org/10.1136/archdischild-2016-310863.3 doi: 10.1136/archdischild-2016-310863.3. [DOI]
  11. Hughes RG, Brocklehurst P, Steer PJ, Heath P, Stenson BM, on behalf of the Royal College of Obstetricians and Gynaecologists. Prevention of Early-onset neonatal Group B streptococcal disease: green-top Guideline No. 36. BJOG An Int J Obstet Gynaecol 2017;124:e280–305. https://doi.org/10.1111/1471-0528.14821 doi: 10.1111/1471-0528.14821. [DOI]
  12. Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of Perinatal Group B Streptococcal Disease – Revised Guidelines from CDC, 2010. 2010;59:1–36.
  13. Verani JR, Spina NL, Lynfield R, Schaffner W, Harrison LH, Holst A, et al. Early-onset group B streptococcal disease in the United States: potential for further reduction. Obstet Gynecol 2014;123:828–37. https://doi.org/10.1097/AOG.0000000000000163 doi: 10.1097/AOG.0000000000000163. [DOI] [PMC free article] [PubMed]
  14. Okike IO, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebody B, Ladhani SN, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged < 90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis 2014;59:e150–7. https://doi.org/10.1093/cid/ciu514 doi: 10.1093/cid/ciu514. [DOI] [PubMed]
  15. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Bacterial meningitis in the United States, 1998–2007. N Engl J Med 2011;364:2016–25. https://doi.org/10.1056/NEJMoa1005384 doi: 10.1056/NEJMoa1005384. [DOI] [PubMed]
  16. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976;294:753–6. https://doi.org/10.1056/NEJM197604012941404 doi: 10.1056/NEJM197604012941404. [DOI] [PubMed]
  17. Heath PT. Status of vaccine research and development of vaccines for GBS. Vaccine 2016;34:2876–9. https://doi.org/10.1016/j.vaccine.2015.12.072 doi: 10.1016/j.vaccine.2015.12.072. [DOI] [PubMed]
  18. Madhi SA, Dangor Z, Heath PT, Schrag S, Izu A, Sobanjo-Ter Meulen A, Dull PM. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 2013;31(Suppl. 4):D52–7. https://doi.org/10.1016/j.vaccine.2013.02.029 doi: 10.1016/j.vaccine.2013.02.029. [DOI] [PubMed]
  19. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001;37:S34–6. https://doi.org/10.1046/j.1440-1754.2001.00738.x doi: 10.1046/j.1440-1754.2001.00738.x. [DOI] [PubMed]
  20. Dangor Z, Kwatra G, Izu A, Lala SG, Madhi SA. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines 2015;14:135–49. https://doi.org/10.1586/14760584.2014.953939 doi: 10.1586/14760584.2014.953939. [DOI] [PubMed]
  21. Lin FY, Philips JB, Azimi PH, Weisman LE, Clark P, Rhoads GG, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001;184:1022–8. https://doi.org/10.1086/323350 doi: 10.1086/323350. [DOI] [PubMed]
  22. Lin FY, Weisman LE, Azimi PH, Philips JB, Clark P, Regan J, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004;190:928–34. https://doi.org/10.1086/422756 doi: 10.1086/422756. [DOI] [PubMed]
  23. Le Doare K, Kampmann B, Vekemans J, Heath PT, Goldblatt D, Nahm MH, et al. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis 2019;19:e162–e171. https://doi.org/10.1016/S1473-3099(18)30659-5 doi: 10.1016/S1473-3099(18)30659-5. [DOI] [PubMed]
  24. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004;363:292–4. https://doi.org/10.1016/S0140-6736(03)15389-5 doi: 10.1016/S0140-6736(03)15389-5. [DOI] [PubMed]
  25. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981;68:544–9. [PubMed]
  26. GOV.UK. Screening Pregnant Women for GBS Not Recommended. URL: www.gov.uk/government/news/screening-pregnant-women-for-gbs-not-recommended (accessed September 2019).
  27. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521–8. https://doi.org/10.1016/S0140-6736(14)60686-3 doi: 10.1016/S0140-6736(14)60686-3. [DOI] [PubMed]
  28. Roberts JN, Gruber MF. Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine 2015;33:966–72. https://doi.org/10.1016/j.vaccine.2014.12.068 doi: 10.1016/j.vaccine.2014.12.068. [DOI] [PubMed]
  29. Royal College of Obstetrics and Gynaecology. Group B Streptococcal Disease, Early-Onset (Green-top Guideline No. 36). URL: www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg36/ (accessed September 2019).
  30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. https://doi.org/10.1016/j.jbi.2008.08.010 doi: 10.1016/j.jbi.2008.08.010. [DOI] [PMC free article] [PubMed]
  31. World Health Organization. Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region. 2012. URL: www.ncbi.nlm.nih.gov/books/NBK143264/ (accessed 18 February 2019). [PubMed]
  32. Pushpa-Rajah A, Bradshaw L, Dorling J, Gyte G, Mitchell EJ, Thornton J, Duley L, Cord Pilot Trial Collaborative Group. Cord pilot trial – immediate versus deferred cord clamping for very preterm birth (before 32 weeks gestation): study protocol for a randomized controlled trial. Trials 2014;15:258. https://doi.org/10.1186/1745-6215-15-258 doi: 10.1186/1745-6215-15-258. [DOI] [PMC free article] [PubMed]
  33. Kenyon S, Ewer A. Obtaining Valid Consent to Participate in Perinatal Research Where Consent is Time Critical. Clinical Governance Advice No. 6a. London: Royal College of Obstetricians and Gynaecologists; 2016. URL: www.rcog.org.uk/en/guidelines-research-services/guidelines/clinical-governance-advice-6a/ (accessed October 2019).
  34. Duley L, Dorling J, Pushpa-Rajah A, Oddie SJ, Yoxall CW, Schoonakker B, et al. Randomised trial of cord clamping and initial stabilisation at very preterm birth. Arch Dis Child Fetal Neonatal Ed 2018;103:F6–14. https://doi.org/10.1136/archdischild-2016-312567 doi: 10.1136/archdischild-2016-312567. [DOI] [PMC free article] [PubMed]
  35. Denison FC, Norrie J, Lawton J, Norman JE, Scotland G, McPherson GC, et al. A pragmatic group sequential, placebo-controlled, randomised trial to determine the effectiveness of glyceryl trinitrate for retained placenta (GOT-IT): a study protocol. BMJ Open 2017;7:e017134. https://doi.org/10.1136/bmjopen-2017-017134 doi: 10.1136/bmjopen-2017-017134. [DOI] [PMC free article] [PubMed]
  36. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2104. doi: 10.1016/S0140-6736(17)30638-4. [DOI] [PMC free article] [PubMed]
  37. Knight M, Chiocchia V, Partlett C, Rivero-Arias O, Hua X, Hinshaw K, et al. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet 2019;393:2395–403. https://doi.org/10.1016/S0140-6736(19)30773-1 doi: 10.1016/S0140-6736(19)30773-1. [DOI] [PMC free article] [PubMed]

RESOURCES